MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2024

”Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months”   January – MarchFinancial summary for the quarter · Net turnover amounted to SEK 0.5 (0.4) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -26.7 (-18.9) million. Basic and diluted earnings per share amounted to SEK -0.23 (-0.34) and SEK -0.23 (-0.34) respectively. · Cash flow from operating